Macko Todd D 4

What Happened

• Todd D. Macko, Chief Financial Officer of Impact Biomedical, reported two sales of company stock: 1,600 shares sold on 2026-03-25 at $0.60 (proceeds $961) and 43,400 shares sold on 2026-03-27 at $0.56 (proceeds $24,369). Both transactions are coded as sales (open market/private sale). Total reported proceeds ≈ $25,330.
• These were outright sales (not purchases or option exercises). Sales are often routine liquidity events; they do not necessarily indicate a change in the insider’s view of the company.

Key Details

• Transaction dates and prices:
  • 2026-03-25 — 1,600 shares at $0.60, proceeds $961
  • 2026-03-27 — 43,400 shares at $0.56, proceeds $24,369
• Transaction type: S = Sale (open market or private sale)
• Filing date: Form 4 filed 2026-03-30. The 3/25 sale appears to have been reported late (Form 4 is generally due within two business days of the transaction); the 3/27 sale may be within the reporting window. Check the full filing for any company notes on timeliness.
• Shares owned after the transactions: not specified in the summary provided here — see the full Form 4 for "Owned After" amounts.
• No 10b5-1 trading plan, tax-withholding, or additional footnotes were indicated in the information provided here (review the Form 4 text for any such disclosures).

Context

• The combined proceeds (~$25k) are relatively small in dollar terms; small-dollar insider sales are often for personal liquidity and are less informative about company prospects than purchases.
• As with any insider transaction, this is factual disclosure of activity only — it should be considered alongside other filings, company fundamentals, and market information before drawing investment conclusions.